| Index | — | P/E | — | EPS (ttm) | -0.54 | Insider Own | — | Shs Outstand | 148.99M | Perf Week | -5.15% |
| Market Cap | 1.07B | Forward P/E | — | EPS next Y | -0.10 | Insider Trans | -0.03% | Shs Float | 106.40M | Perf Month | -8.99% |
| Enterprise Value | 1.18B | PEG | — | EPS next Q | -0.06 | Short Float | 12.55% | Perf Quarter | 11.82% | ||
| Income | -78.00M | P/S | 5.13 | EPS this Y | — | Short Ratio | 4.18 | Perf Half Y | 89.71% | ||
| Sales | 209.00M | P/B | 3.01 | EPS next Y | — | ROA | -12.82% | Short Interest | 13.35M | Perf YTD | 121.23% |
| Book/sh | 2.39 | P/C | 15.30 | EPS next 5Y | — | ROE | -35.42% | 52W High | 9.42 -20.59% | Perf Year | 128.98% |
| Cash/sh | 0.47 | P/FCF | — | EPS past 3/5Y | — | ROIC | 16.91% | 52W Low | 2.55 193.33% | Perf 3Y | 12.70% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -40.50% -8.12% | Gross Margin | 34.61% | Volatility | 7.82% 7.13% | Perf 5Y | -82.95% |
| Dividend TTM | — | EV/Sales | 5.64 | EPS Y/Y TTM | — | Oper. Margin | 46.02% | ATR (14) | 0.52 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.98 | Sales Y/Y TTM | -2.79% | Profit Margin | -37.07% | RSI (14) | 46.61 | Recom | 2.57 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.05 | EPS Q/Q | 75.00% | SMA20 | -2.76% | Beta | 0.62 | Target Price | 7.00 |
| Payout | 0.00% | Debt/Eq | 0.50 | Sales Q/Q | 8.51% | SMA50 | -3.73% | Rel Volume | 0.71 | Prev Close | 7.19 |
| Employees | 415 | LT Debt/Eq | 0.49 | Earnings | Nov 04 | SMA200 | 36.88% | Avg Volume | 3.21M | Price | 7.48 |
| IPO Date | Nov 20, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 54.05% 5.69% | Net Debt/EBITDA | — | Volume | 2,292,419 | Change | 4.03% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Neutral | $8.00 |
| May-08-26 | Reiterated | Deutsche Bank | Buy | $4.50 → $6.00 |
| Dec-15-25 | Reiterated | Wells Fargo | Overweight | $4.50 |
| Mar-21-25 | Reiterated | Stifel Nicolaus | $10 → $5.00 | |
| Feb-26-25 | Downgrade | Baird | Outperform → Neutral | |
| Dec-05-24 | Downgrade | Goldman Sachs | Neutral → Sell | |
| Nov-08-24 | Downgrade | William Blair | Outperform → Market Perform | |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal Weight | |
| May-09-24 | Reiterated | Robert W. Baird | $8.00 → $10 | |
| Dec-12-23 | Upgrade | B of A Securities | Neutral → Buy |
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 209 | 186 | 259 | 289 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 137 | 152 | 151 | 149 | — | — | — | — | — | |
| Gross Profit | 73 | 33 | 108 | 140 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 152 | 171 | 162 | 151 | — | — | — | — | — | |
| Research and Development | 22 | 23 | 19 | 17 | — | — | — | — | — | |
| Other Operating Expense | -198 | -154 | 163 | 4 | — | — | — | — | — | |
| Operating Income | 95 | -7 | -236 | -32 | — | — | — | — | — | |
| Interest Expense | 25 | 27 | 48 | 46 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -209 | -201 | 22 | 695 | — | — | — | — | — | |
| Net Income Before Taxes | -137 | -235 | -261 | 618 | — | — | — | — | — | |
| Income Taxes | 0 | -4 | -2 | 756 | — | — | — | — | — | |
| Consolidated Net Income | -78 | -131 | -145 | -119 | — | — | — | — | — | |
| Net Income From Continuing Operations | -136 | -231 | -260 | -138 | — | — | — | — | — | |
| Net Income | -78 | -131 | -145 | -119 | — | — | — | — | — | |
| EPS (Recurring) | -0.54 | -0.91 | -1.05 | -0.90 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.54 | -0.91 | -1.05 | -0.90 | — | — | — | — | — | |
| EPS (Diluted) | -0.54 | -0.91 | -1.05 | -0.90 | — | — | — | — | — | |
| EBITDA | -56 | -148 | -157 | 712 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.30 | 2.53 | 2.90 | 2.99 | — | — | — | — | — | |
| Gross Margin | 34.93 | 17.74 | 41.70 | 48.44 | — | — | — | — | — | |
| Operating Margin | 45.45 | -3.76 | -91.12 | -11.07 | — | — | — | — | — | |
| Net Margin | -37.32 | -70.43 | -55.98 | -41.18 | — | — | — | — | — | |
| Shares Outstanding | 148 | 145 | 138 | 132 | — | — | — | — | — | |
| Market Capitalization | 1,107 | 471 | 752 | 865 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ORESHACK KURT | General Counsel | Jun 10 '26 | Sale | 5.10 | 25,000 | 127,500 | 335,767 | Jun 10 |
| ORESHACK KURT | General Counsel | Jun 09 '26 | Sale | 5.06 | 25,000 | 126,500 | 360,767 | Jun 10 |
| LUCIER GREGORY T | Director | Dec 08 '25 | Buy | 3.67 | 48,528 | 178,098 | 155,123 | Dec 09 |
| LUCIER GREGORY T | Director | Dec 05 '25 | Buy | 3.70 | 51,472 | 190,446 | 106,595 | Dec 09 |
| Brust Bernd | Chief Executive Officer | Nov 13 '25 | Buy | 3.25 | 216,212 | 702,689 | 466,771 | Nov 17 |
| Brust Bernd | Chief Executive Officer | Nov 12 '25 | Buy | 3.21 | 93,358 | 299,679 | 250,559 | Nov 13 |
| Brust Bernd | Chief Executive Officer | Nov 11 '25 | Buy | 3.24 | 157,201 | 509,331 | 157,201 | Nov 13 |
| ORESHACK KURT | General Counsel | Jan 31 '25 | Sale | 5.03 | 25,000 | 125,750 | 167,618 | Jan 31 |
| DeFord John A | Director | Nov 12 '24 | Buy | 5.75 | 17,500 | 100,625 | 70,046 | Nov 14 |
| HULL CARL | Director, Officer | Nov 11 '24 | Buy | 5.64 | 175,000 | 987,000 | 175,000 | Nov 12 |
| GTCR INVESTMENT XI LLC | Director, 10% Owner | May 28 '24 | Sale | 9.81 | 9,940,974 | 97,570,660 | 20,150,005 | May 30 |
| HULL CARL | Chief Executive Officer | Nov 25 '20 | Buy | 26.94 | 35,000 | 942,900 | 35,000 | Nov 30 |
| ORESHACK KURT | General Counsel | Nov 24 '20 | Buy | 27.00 | 7,500 | 202,500 | 7,500 | Nov 25 |
| GRAY SUSANNAH | Director | Nov 24 '20 | Buy | 27.00 | 20,000 | 540,000 | 31,852 | Nov 25 |
| SELLERS LISA | Officer | Nov 24 '20 | Buy | 27.00 | 18,888 | 509,976 | 18,888 | Nov 25 |